A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients

To assess the effect of SR147778 on weight loss over a period of 24 weeks when prescribed with a hypocaloric diet in obese patients.

Obesity is becoming a major health problem in western societies. Its prevalence is increasing especially in USA, UK, and Germany. Obesity is responsible for increased morbidity and mortality. The comorbid conditions associated with obesity include hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, respiratory dysfunction, sleep apnea, gout, gallbladder disease, osteoarthritis, and cancer